1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22
2. Cederholm-Williams SA, Houlbrook S, Porter NW, Marshall JM, Chissic H (1985) Characterisation of plasminogen activators secreted by human malignant cells. In Treatment of Metastasis: Problems and Prospects, Hellmann K, Eccles SA (eds) pp 347–350. London: Taylor & Francis
3. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G (2002) Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 160: 237–246
4. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jänicke F, Meijer-van Gelder ME, Henzen-Longmans SC, van Putten WL, Klijn JG (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636–643
5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521